A Large Family with Hereditary MTC: Role of RET Genetic Analysis in Differential Diagnosis Between MEN 2A and FMTC

Germline mutations of the RET proto-oncogene cause three different cancer syndromes: multiple endocrine neoplasia type 2A (MEN 2A), multiple endocrine neoplasia type 2B (MEN 2B) and familial medullary thyroid carcinoma (FMTC). In the absence of biochemical and/or clinical evidence of pheochromocytoma and hyperparathyroidism, patients with MEN 2A disease display the same phenotype of FMTC disease, although prognosis and clinical management in both affected and unaffected familial members are quite different. We studied a family with hereditary MTC, whose proband was referred to us because of enlarged cervical nodes and increased calcitonin serum levels 28 years after the total thyroidectomy for MTC. Cervical node dissection was carried out and subsequently the presence of MTC metastasis was histologically confirmed. A RET genomic mutation at codon 634 (TGC→TTC) was identified in the proband and in seven out of 19 familial members studied. Accordingly, a hereditary disease was suggested. However, the strong association of RET mutation at codon 634 with the presence of pheochromocytoma in MEN 2 disease suggested a more rigorous management in all gene carriers. Indeed, during the follow-up pheochromocytoma was subsequently identified in the proband. This finding suggests that all families with a pedigree suggestive of FMTC should be regarded at risk from MEN 2A disease, at least when a critical mutation in the RET cysteine domain is detected.

Key words:

Multiple Endocrine Neoplasia 2A (MEN 2A) - Familial Medullary Thyroid Carcinoma (FMTC) - RET Proto-Oncogene - Mutation - Genetic Analysis

References

• 1 Schimke R N. Genetic aspects of multiple endocrine neoplasia.  Ann Rev Med. 1984;  35 25-31
• 2 Schimke R N, Hartmann W H, Prout T E, Rimoin D L. Syndrome of bilateral pheochromocytoma, medullary thyroid carcinoma and multiple neuromas: a possible regulatory defect in the differentiation of cromaffin tissue.  N Engl J Med. 1968;  279 1-7
• 3 Farndon J R, Leight G S, Dilley W G, Baylin S B, Smallridge R C, Harrison T S, Wells S A Jr. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity.  Br J Surg. 1986;  73 278-281
• 4 Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel R, van Hamstel H KP, Lips C JM, Nishisho I, Takai S, Marsh D J, Robinson B G, Frank-Raue K, Raue F, Xue F, Noll W W, Romei C, Pacini F, Fink M, Niederle B, Zedenius J, Nordenskiold M, Komminoth P, Hendy G N, Gharib H, Thibodeau S N, Lacroix A, Frilling A, Ponder B AJ, Mulligan L M. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2.  JAMA. 1996;  276 1575-1579
• 5 Ponder B AJ. The phenotype associated with ret mutations in the Multiple Endocrine Neoplasia type 2 syndrome.  Cancer Res. 1999;  59 (Suppl) 1736-1742
• 6 Moers A M, Landsvater R M, Schaap C, Jansen-Schillhorn van Veen J M, de Valk I A, Blijiham J H, Hoppener J W, Vroom T M, van Amstel H K, Lips C J. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.  Am J Med. 1996;  101 635-641
• 7 Takahashi M, Buma Y, lwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the RET proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains.  Oncogene. 1988;  3 571-578
• 8 Chiefari E, Russo D, Giuffrida D, Zampa G A, Meringolo D, Arturi F, Chiodini I, Bianchi D, Attard M, Trischitta V, Bruno R, Giannasio P, Pontecorvi A, Filetti S. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.  J Endocrinol Invest. 1998;  21 358-364
• 9 Russo D, Arturi F, Chiefari E, Meringolo D, Bianchi D, Bellanova B, Filetti S. A case of metastatic medullary thyroid carcinoma: early identification before surgery of a RET proto-oncogene somatic mutation in fine needle aspirate specimen.  J Clin Endocrinol Metab. 1997;  82 3378-3382
• 10 Baudin E, Lumbroso J, Schlumberger M, Leclere J, Giammarile F, Gardet P, Roche A, Travagli J P, Parmentier C. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.  J Nucl Med. 1996;  37 912-916
• 11 Cryer P E. Disease of Sympathetic-Chromaffin System. In: Felig P, Baxter JD, Frohman LA (III ed) Endocrinology and Metabolism.  New York; McGraw Hill, Inc. 1997
• 12 Learoyd D L, Twigg S M, Marsh D J, Robinson B G. The pratical management of multiple endocrine neoplasia.  Trends Endocrinol Metab. 1995;  6 273-278
• 13 Chappuis-Flament S, Pasini A, De Vita G, Segouffin-Cariou C, Fusco A, Attie T, Lenoir G M, Santoro M, Billaud M. Dual effect on the RET receptor of MEN 2 mutations affecting specific extracytoplasmatic cysteines.  Oncogene. 1998;  17 2851-2861
• 14 Libroia A, Verga U, Vecchi G, Banfi F, Zurleni F, Quadro L, Scurini C, Fattoruso O, Colantuoni V. Seventeen-year-long follow-up of a family affected by type 2A multiple endocrine neoplasia (MEN 2A).  J Endocrinol Invest. 1998;  21 87-92
• 15 Gagel R F. Unresolved issues in the genesis and management of multiple endocrine neoplasia type 2.  Horm Metab Res. 1997;  29 135-137